Vitamin K - Anti-haemorrhagic Vitamin

Vitamin K is a fat-soluble vitamin. It is essential for the production of protein called prothrombin and other factors involved in the blood-clotting mechanism. Hence it is known to prevent haemorrhages.

Vitamin K exists in nature in two forms. Vitamin K1, originally isolated from lucrene (alfalfa), is the only form that occurs in plants. It is a yellow oil, soluble in fat solvents, but only slightly soluble in water. Vitamin K2 has been found to be produced by many bacteria.

Vitamin K is not easily destroyed by light, heat, or exposure to air. It is, however, destroyed by strong acids, alkalis, and oxidising agents, X-rays and radiation, frozen foods, aspirin, air pollution, and mineral oil are other factors that can destroy vitamin K.

Studies of the liver stores of vitamin K indicate that approximately 50% of the vitamin comes from the diet and 50% from bacterial production in the intestines. Vitamin K is absorbed along with fat in the diet. Bile is essential for its absorption. The absorbed vitamin passes through the lymphatic system to the general circulation. The liver stores appreciable amounts of this vitamin. There is hardly any excretion of vitamin K by the body.

Recommended Daily Allowance - Vitamin K
Men 70-140 mcg
Women 70-140 mcg
Children 35-75 mcg
More on Vitamin K
Vitamin K Benefits
Vitamin K Deficiency Symptoms
Vitamin K Sources

Leave your comments

Health News

Surgeon Removes Eight Pound Liver Tumor

The cancerous tumor in Marcus Muhich's liver weighed 8 pounds and was nearly a foot across. Doctors at three major academic medical centers in the Midwest told Muhich his high-grade tumor was inoperable. Then he was referred to Dr... [ read article ]

NIPPV Linked To Increased Hospital Mortality Rates In Small Group Of Patients

Although increased use of noninvasive positive-pressure ventilation (NIPPV) nationwide has helped decrease mortality rates among patients hospitalized with chronic obstructive pulmonary disease (COPD), a small group of... [ read article ]

FDA Approves Label Update For PREZISTA® To Include 192-Week Data In HIV-1-Infected Adult Patients

Starting Treatment Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study... [ read article ]

Recommended Stuff

Our Latest Blog Entries...